

REMARKS

Claims 1-14 are pending in the case. Claims 11, 12, and 14 have been amended. Basis for the Amendment to Claim 14 can be found in the Application as originally filed; in particular, basis can be found on page 2, lines 6-17. Applicants assert that the present Amendments add no new matter.

The Examiner has set forth a restriction requirement under 35 U.S.C. §121. Applicants have been requested to elect one of the following species set forth in Claim 11: inflammatory diseases related to arthritis, asthma, ulcerative colitis, inflammatory bowel disease, Crohn's disease, sepsis, or endotoxemia. The Examiner has alleged that Claims 8-10 are generic.

In response to the Requirement for Restriction Election Applicants elect the species of inflammatory diseases related to arthritis.

Applicants: Scott R. Presnell et al.

Serial No.: 10/806,294

Filed: March 22, 2004

For: NOVEL CYTOKINE ZCYTO18

Early consideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6672.

Respectfully Submitted,



Shelby J. Walker
Registration No. 45,192

Enclosure:

Amendment Fee Transmittal (in duplicate)

Customer No. 10117

ZymoGenetics, Inc.

1201 Eastlake Avenue East

Seattle, Washington 98102